Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening

doi 10.1021/acs.jmedchem.7b01605.s002
Full Text
Abstract

Available in full text

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)

Related search

Computational Design of Druglike Allosteric Inhibitors of AXL and MET Receptor Tyrosine Kinases

Biophysical Journal
Biophysics
2019English

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer

The Scientific World Journal
BiochemistryMedicineGeneticsMolecular BiologyEnvironmental Science
2004English

Ligand-Based Drug Design of Novel Aldose Reductase Inhibitors

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2018English

Exploring Receptor Tyrosine Kinases-Inhibitors in Cancer Treatments

Egyptian Journal of Medical Human Genetics
Genetics
2019English

Allosteric Regulation of EGF Receptor Ligand Binding by Tyrosine Kinase Inhibitors

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2018English

Signaling by Receptor Tyrosine Kinases

Annual Review of Biochemistry
Biochemistry
1993English

Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2013English

Discovery of Novel Dual Inhibitors of Receptor Tyrosine Kinases EGFR and IGF-1R

Journal of Enzyme Inhibition and Medicinal Chemistry
MedicineDrug DiscoveryPharmacology
2017English

Biased Ligand Quantification in Drug Discovery: From Theory to High Throughput Screening to Identify New Biased Μ Opioid Receptor Agonists

British Journal of Pharmacology
Pharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy